RxDoctor Payments DataLook up a doctor →

Polly Niravath, MD

Internal Medicine · Houston, TXNPI 1710123088

Payments from drug & device makers

$2,879,756in general payments, 2019–2025

Across 242 payments — averaging $11,900 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.1M
  • Novartis$1M
  • Daiichi Sankyo Inc.$480K
  • Genentech, Inc.$183K
  • Gilead$37K
  • Hoffmann-la Roche Limited$17K
  • plus $26K from 11 others

What the payments were for

  • Consulting fees$8,19778%
  • Speaking & faculty fees$1,30012%
  • Food & beverage$6796%
  • Education$3293%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,879,756 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$82,170
Medicare patients
308
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib29$461,033
KisqaliRibociclib Succinate17$207,159
Exemestane39$3,946
Tamoxifen Citrate138$3,493
Letrozole107$2,462
Fentanyl12$1,951
Anastrozole102$1,601
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$917
Gabapentin53$549
Ibandronate Sodium16$542
Duloxetine Hcl27$458
Oxybutynin Chloride13$303
Mirtazapine23$288
Spironolactone15$205
Alendronate Sodium32$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$228$461,03329 claims
NovartisKisqali$1,010,923$207,15917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →